Sun Pharmaceutical Industries Ltd.

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Google Cloud's commitment to AI-powered cancer research and Sun Pharma's partnership with a music icon. NEW YORK, April 11, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, April 7-11, 2025. Google Cloud and Ai2 Commit $20M to Advance AI-Powered Research for the Cancer AI Alliance Through the partnership, Google Cloud will power planet-scale AI infrastructure and data analytics tools, while Ai2 will provide critical expertise in training large-scale models focusing on cancer research. Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis for The First Time in Partnership with Sun Pharma 8X Grammy Award-winning artist and Rock and Roll Hall of Fame inductee, Art Garfunkel, reveals his experience with ILUMYA® (tildrakizumab-asmn), stating, "I am finally ready to give my history with psoriasis a voice." H.I.G. Capital Completes Acquisition of GetixHealth "GetixHealth is a vital partner to healthcare providers, including many of the nation's largest health systems," says Anthony Chambers, Managing Director at H.I.G., referencing GetixHealth's revenue cycle management (RCM) solutions and comprehensive suite of services. CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19. Breakthrough Prize Announces 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics "This year's Breakthrough Prize laureates have made amazing strides – including treatments for major diseases affecting millions of people worldwide – showing once again the transformative power of curiosity-driven basic science," said Priscilla Chan and Mark Zuckerberg. Proprio Receives FDA Clearance For the World's First AI Surgical Guidance Platform This is the first-ever technology that enables 3D, dynamic and segmental viewing of the anatomy, and marks the first time in history that surgeons will be able to measure success in real-time during surgery. Healthcare Brands to Gain Enhanced Engagement through CMI Media Group and Compas Collaboration with Microsoft Advertising "This represents a major milestone for the healthcare industry combining valuable expertise and reach. With this unique agreement, we can offer all of our clients expanded benefits to engaging with us for their search engine marketing and display investments," said Justin Freid, Chief Media & Innovation Officer, CMI Media Group. LG Expands Mental Health Support for NCAA Final Four Host Schools with NAMI Partnership The donation will enable each university's NAMI on Campus club to expand its programming, increase awareness of mental health resources and provide peer support for students facing challenges. In addition, each university will receive LG's innovative Counter-Depth MAX™ refrigerator with Zero Clearance™ for their student meeting spaces. Health Advocates Team-Up with #WearSunscreen Campaign to Spread the Word About Sun Safety "Just like brushing your teeth or clicking your seatbelt, wearing sunscreen should be a consistent part of your daily routine all year long," said Dr. Jane Yoo, a board-certified dermatologist and dermatologic surgeon in New York City. MADD and Nationwide Launch "Prom Promise" Campaign to Help Parents Prevent Underage Drinking This Prom Season At the heart of the Prom Promise campaign is MADD's Prom Promise Contract — an agreement parents and teens sign together to commit to a safe, substance-free prom night. Through this pledge, families establish clear expectations, boundaries, and a shared understanding of the serious risks associated with underage substance use and impaired driving. New Survey Reveals Nearly 75% of Nurses Unaware of Potential Health Risks in IV Bags Nearly 75% of nurses polled were unaware that the majority of IV bags used in the U.S. contain Di(2-ethylhexyl) Phthalate (DEHP), and more than 50% were unaware that the state of California has determined DEHP to be a reproductive and developmental toxicant and carcinogen. Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease "Quest's AD-Detect suite of advanced diagnostics has grown to include a range of validated blood-based biomarkers, giving providers options for personalizing testing for the individual patient," said Kathleen Valentine, Vice President and General Manager, Neurology, Quest Diagnostics. New Landmark Study Reveals Brain Blood Flow as Key Biomarker in Depression--Amen Clinics Plays Pivotal Role This landmark research demonstrates that functional brain changes—specifically decreased blood flow—are more accurate markers of depression than structural brain changes like cortical thinning, which have historically shown weak and inconsistent associations. AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission. Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

India and China, the two principal suppliers of generic drugs to the US market, are anticipated to be significantly affected. Credit: Mr.Boyz/Shutterstock. US President Donald Trump has stated that the country is set to announce “major tariffs” on pharmaceutical imports soon, as reported by Reuters . According to the President, the move will incentivise drug companies to relocate their operations to the US. The announcement is expected as the “discounted” reciprocal tariffs, previously declared, are due to take effect from 9 April 2025, as reported in the Business Standard . Despite not naming specific countries, it is anticipated that India and China, the two principal suppliers of generic drugs to the US market, are expected to be significantly affected. Trump also stated that the new tariffs would result in drug companies swiftly returning to the US due to its substantial market share. He noted that the companies would depart from other regions, including China, once the tariffs are in place. Following the imposition of an additional 50% tariff on China, which was requested to lower its retaliatory tariff of 34% but did not do so, China’s total tariffs now stand at 104%. Trump has consistently championed the cause of increasing domestic pharmaceutical production and previously vowed to implement tariffs to bolster the country’s manufacturing capacity. Although he alluded to the announcement of tariffs on pharmaceutical imports on 24 March 2025, he did not provide a specific timeline. According to The Times of India, Indian pharmaceutical stocks have taken a hit in response to the tariff threats, with the Nifty Pharma index falling by 1.7%, contributing to a broader decline in the Nifty 50 benchmark. Lupin, Gland Pharma and Zydus Lifesciences saw significant losses, with shares dropping between 3% and 5%. Sun Pharma and Cipla also experienced declines.

8X Grammy Award-winning artist and Rock and Roll Hall of Fame inductee reveals his experience with ILUMYA®(tildrakizumab-asmn) as part of the "I LUV YA for The Long Haul" campaign. PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- Today, Sun Pharma announced its partnership with music icon and ILUMYA® (tildrakizumab-asmn) patient, Art Garfunkel, as he shares his story of living with moderate-to-severe plaque psoriasis in-depth for the first time publicly. Art, who was named one of Rolling Stone's "100 Greatest Singers of All Time," launched his career in the acclaimed duo "Simon & Garfunkel." Through the "I LUV YA for The Long Haul" campaign, Art joins a community of ILUMYA patients shedding light on the emotional toll of psoriasis and empowering others living with the condition to find the best treatment for them. While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up.1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now. "With support from my wife, Kim, and a treatment I trust, I am finally ready to give my history with psoriasis a voice," said Art. "After struggling for decades, I finally started ILUMYA about two years ago, and experiencing clearer skin has helped me regain my confidence. I am excited to share my story as part of the I LUV YA campaign in the hope that it will encourage others to find the right treatment for them." The "I LUV YA for The Long Haul," originally launched in May 2024, highlights the emotional impact psoriasis can have on a patient's life and how support – whether that be from a doctor, friend, or family member – can help navigate the challenges of managing their condition. The multi-part video series highlights real-life patient stories, including Art and how his wife, Kim, provided that support for him. "We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has beyond the physical symptoms," said Maureen Shannon, Head of Biologics Marketing at Sun Pharma. "Art's music has impacted millions and his experience, shared for the first time, is sure to leave a lasting impression." To learn more about Art Garfunkel's experience and to learn more about ILUMYA as a treatment option, visit ILUMYA.com/ILuvYa. About Plaque Psoriasis Plaque psoriasis is a chronic, autoimmune disease that results in an overactive immune system and causes inflammation in the body, leading to symptoms like plaques, redness and flakes. It is estimated that nearly 8 million Americans live with plaque psoriasis.1 In plaque psoriasis, skin cells grow more rapidly than normal, rising to the surface of the skin in days rather than weeks. Life with plaque psoriasis can also be more than the physical symptoms – there can be an emotional impact as well. About ILUMYA (tildrakizumab-asmn) ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in Australia and Japan, and under the brand name ILUMETRI® in Europe, where it is marketed by Almirall. INDICATIONS AND USAGE ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hypersensitivity Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. Infections ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves. Pretreatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment. Immunizations Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines. Adverse Reactions The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea. Please see Full Prescribing Information. About Sun Pharmaceutical Industries Limited Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit & follow us on LinkedIn & X (Formerly Twitter). Disclaimer Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. References SOURCE Sun Pharmaceutical Industries Inc., USA (Sun Pharma) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED